Quinuclidinone analogues as anticancer agents
US-2024217964-A1 · Jul 4, 2024 · US
US2016200726A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016200726-A1 |
| Application number | US-201414913736-A |
| Country | US |
| Kind code | A1 |
| Filing date | Aug 14, 2014 |
| Priority date | Sep 6, 2013 |
| Publication date | Jul 14, 2016 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A 9-azabicyclo[3.3.1]nonan-3-one derivative is reacted with a hydrogen in the presence of a catalyst composed of a ruthenium complex to obtain, at a low cost, an endo-9-azabicyclo[3.3.1]nonan-3-ol derivative useful as a production intermediate for agrochemical agents or medicines.
Opening claim text (preview).
1 . A method for producing a compound represented by formula (II), comprising reacting a compound represented by formula (I) with a hydrogen in a presence of a catalyst consisting of a ruthenium complex: in the formulae (I) and (II), R represents a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aralkyl group, or an unsubstituted or substituted alkoxycarbonyl group. 2 . The method according to claim 1 , wherein the ruthenium complex is a compound represented by the following formula: Ru(X)(Y)(Px) n (L) or Ru(X)(Y)(PN) 2 , in the formulae, X and Y each independently represents an anionic ligand, Px represents a phosphine ligand, n represents 1 or 2, L represents a ligand represented by the following formula (III) or a diamine ligand, and PN represents a ligand represented by the following formula (IV): in the formulae, R 1 and R 2 each independently represents a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, or an unsubstituted or substituted aralkyl group, a ring B represents an unsubstituted or substituted hetero ring, a double line portion consisting of a continuous line and a dotted line represents a single bond or a double bond, Z represents a coordinating atom selected from the group consisting of N, P, O, and S, R 3 and R 4 each independently represents an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, or an unsubstituted or substituted aralkyl group, and A represents an unsubstituted or substituted C1 to 4 alkylene group. 3 . The method according to claim 2 , wherein the ruthenium complex is a compound represented by the formula: Ru(X)(Y)(Px) n (L), and L represents a pyridin-2-yl methanamine, a (1-methyl-1H-benzimidazol-2-yl)methanamine, a (5-methylpyrazin-2-yl) methanamine, a benzoxazol-2-yl methanamine, a pyrimidin-2-yl methanamine, a thiazol-2-yl methanamine, or a (pyrazin-2-yl)methanamine. 4 . The method according to claim 2 , wherein the ruthenium complex is a compound represented by the formula: Ru(X)(Y)(Px) n (L), and L represents a diamine ligand represented by the following formula (VI); wherein, R 5 to R 12 each independently represents a hydrogen atom, an unsubstituted or substituted alkyl group, an unsubstituted or substituted aryl group, or an unsubstituted or substituted aralkyl group, two of R 5 to R 12 may be bonded together to from a ring, D represents a single bond, an unsubstituted or substituted alkylene group, an unsubstituted or substituted cycloalkylene group, an unsubstituted or substituted arylene group, or an unsubstituted or substituted divalent hetero ring group. 5 . The method according to claim 2 , wherein the ruthenium complex is a compound represented by the formula: Ru(X)(Y)(PN) 2 , and PN represents a ligand represented by the following formula (V): 6 . The method according to claim 1 , wherein, in the formulae (I) and (II), R represents an unsubstituted or substituted aralkyl group, and the unsubstituted or substituted aralkyl group is a benzyl group.
Bridged systems · CPC title
containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof · CPC title
with hydrogen or hydrogen-containing gases · CPC title
and phosphine-P atoms as substituents on a ring of the condensed system or on a further attached ring · CPC title
with more than one complexing phosphine-P atom · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.